EUVIMEDEUVIMED entdecken
Open Access

Prevalence of Multi-Antibiotic Resistant Escherichia coli and Klebsiella species obtained from a Tertiary Medical Institution in Oyo State, Nigeria

A A Ayandele, E K Oladipo, O Oyebisi, M O Kaka

Qatar Medical Journal · 03.04.2020 · 2020 (1)

DOI: 10.5339/qmj.2020.9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Qatar Medical Journal, erschienen am 03.04.2020. Verfasst von A A Ayandele und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pure and Applied Biology, Ladoke Akintola University of Technology, Ogbomoso, Nigeria. Die Arbeit wurde bisher 65-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The development of multi-antibiotic resistant bacteria, especially Gram-negative bacteria which are the major cause of hospital-acquired infections worldwide, had been increasing. Escherichia coli and Klebsiella sp. had become more resistant to different classes of antibiotics, and the treatment of infections caused by these bacteria had developed into a challenge in both developed and developing countries. This study had determined the multi-antibiotic resistance (MAR) patterns of Escherichia coli and Klebsiella sp. isolated from clinical inpatient and outpatient samples.

Method

The present study had used 50 E . coli and 48 Klebsiella sp. isolates. Antibiotic susceptibility test had been carried out by using disk diffusion method, and the interpretation of results of the zones of inhibition had accorded with Clinical Laboratory Standards Institute (CLSI). The antibiotics used had included the following: streptomycin, ciprofloxacin, erythromycin, nitrofurantoin, amikacin, gentamicin, ofloxacin, cefepime, oxacillin, colistin sulfate, cefotaxime, ceftazidime, pefloxacine, and cloxacillin.

Results

E. coli and K. pneumoniae had shown high-resistance patterns. E. coli had exhibited high resistance against cloxacillin (96%), oxacillin (96%), erythromycin (88%), and most especially streptomycin (98%). Similarly, K. pneumoniae had presented a high resistance to streptomycin (88%), cloxacillin (92%), oxacillin (92%), and colistin (92%). E. coli had presented the highest multidrug resistance with a MAR index of 1.00. A total of 17 E. coli isolates had shown resistance to the 14 antibiotics tested.

Conclusion

E. coli and Klebsiella sp. in clinical isolates in outpatients and inpatients in Ibadan, Western Nigeria had demonstrated high antimicrobial resistance. Thus, such condition should be considered a major public health concern, and measures must be taken to establish the sources and drivers of this problem.

Schlagwörter

Stichwörter der Autor:innen

Antibiotics ResistanceEscherichia coliKlebsiella sp.Nigeria

Autor:innen und Institutionen

  • Department of Pure and Applied Biology, Ladoke Akintola University of Technology, Ogbomoso, Nigeria.
  • Department of Microbiology, Laboratory of Molecular Biology, Immunology and Bioinformatics, Adeleke University, Ede, Osun State, Nigeria.

Zitieren

APA

Ayandele, A. A., Oladipo, E. K., Oyebisi, O., & Kaka, M. O. (2020). Prevalence of Multi-Antibiotic Resistant Escherichia coli and Klebsiella species obtained from a Tertiary Medical Institution in Oyo State, Nigeria. Qatar Medical Journal, 2020(1). https://doi.org/10.5339/qmj.2020.9

Vancouver

Ayandele AA, Oladipo EK, Oyebisi O, Kaka MO. Prevalence of Multi-Antibiotic Resistant Escherichia coli and Klebsiella species obtained from a Tertiary Medical Institution in Oyo State, Nigeria. Qatar Medical Journal. 2020;2020(1). doi:10.5339/qmj.2020.9

BibTeX
@article{Ayandele2020,
  author = {Ayandele, A A and Oladipo, E K and Oyebisi, O and Kaka, M O},
  title = {Prevalence of Multi-Antibiotic Resistant Escherichia coli and Klebsiella species obtained from a Tertiary Medical Institution in Oyo State, Nigeria},
  journal = {Qatar Medical Journal},
  year = {2020},
  volume = {2020},
  number = {1},
  doi = {10.5339/qmj.2020.9}
}
Kostenlos starten →